Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol.
Journal article
Ontaneda D. et al, (2020), Contemp Clin Trials
Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial.
Journal article
McKee JB. et al, (2019), Mult Scler, 25, 246 - 255
Design and rationale of the determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis (DELIVER-MS) trial
Conference paper
Ontaneda D. et al, (2018), MULTIPLE SCLEROSIS JOURNAL, 24, 470 - 471
Validating the portal population of the United Kingdom Multiple Sclerosis Register.
Journal article
Middleton RM. et al, (2018), Mult Scler Relat Disord, 24, 3 - 10
The Contribution of Fibrinogen to Inflammation and Neuronal Density in Human Traumatic Brain Injury.
Journal article
Jenkins DR. et al, (2018), J Neurotrauma
INFLAMMATION AT THE BLOOD-BRAIN BARRIER: A NOVEL TREATMENT TARGET IN TRAUMATIC BRAIN INJURY
Conference paper
Jenkins D. et al, (2017), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 88, A82 - A82
Trans-synaptic neurodegeneration 12 months following optic neuritis - a longitudinal OCT and DTI study
Conference paper
McKee JB. et al, (2017), MULTIPLE SCLEROSIS JOURNAL, 23, 254 - 255
Personalised medicine for multiple sclerosis care.
Journal article
Gafson A. et al, (2017), Mult Scler, 23, 362 - 369
Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease.
Journal article
Juryńczyk M. et al, (2017), J Neurol Neurosurg Psychiatry, 88, 132 - 136
Amiloride does not protect retinal nerve fibre layer thickness following acute optic neuritis; result from a phase II, double blind, randomised controlled trial.
Presentation
McKee JB. et al, (2016), MULTIPLE SCLEROSIS JOURNAL, 22, 21 - 22
OPTIMISE: User-guided solutions for harmonized clinical and patient-centred data capture
Conference paper
Yong M. et al, (2016), MULTIPLE SCLEROSIS JOURNAL, 22, 454 - 455
Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort.
Journal article
Cranley MR. et al, (2016), J R Army Med Corps, 162, 109 - 114
Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.
Journal article
McGuigan C. et al, (2016), J Neurol Neurosurg Psychiatry, 87, 117 - 125
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Journal article
McKee JB. et al, (2015), BMJ Open, 5
Overlapping CNS inflammatory diseases: differentiating features of NMO and MS.
Journal article
Juryńczyk M. et al, (2015), J Neurol Neurosurg Psychiatry, 86, 20 - 25
AMILORIDE CLINICAL TRIAL IN OPTIC NEURITIS: TRIAL PARADIGM
Conference paper
McKee J. et al, (2014), JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 85
Multimodal clinical trial paradigm to assess neuroprotection in optic neuritis: baseline data
Conference paper
Mckee JB. et al, (2014), MULTIPLE SCLEROSIS JOURNAL, 20, 361 - 361
ASIC1 Blockade in Primary Progressive Multiple Sclerosis: Evidence of Neuroprotection with Amiloride
Journal article
Arun T. et al, (2013), NEUROLOGY, 80
Targeting ASIC1 in primary progressive multiple sclerosis: Evidence of neuroprotection with amiloride
Journal article
Arun T. et al, (2013), Brain, 136, 106 - 115
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Journal article
Arun T. et al, (2013), Brain, 136, 106 - 115